Marisa Wexler, MS,  senior science writer—

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. When the weather is unusually warm, people with multiple sclerosis (MS) are more likely to require emergency medical care,…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. There is a lack of diversity among neurologists, who are disproportionately white men, but new programs aimed at inclusivity may…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. African Americans with relapsing-remitting multiple sclerosis (RRMS) are more likely than white patients — despite comparable disease durations and…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the…

Using artificial intelligence (AI) on imaging data collected from multiple sclerosis (MS) patients, researchers were able to classify these people into three new disease subtypes, each distinct from the current groupings determined by symptoms. These new subtypes may allow doctors to better determine those patients more likely to have…

A gene called Mertk has important roles in the repair of myelin, the fatty substance that surrounds and protects neurons and that is lost in multiple sclerosis (MS). The findings were published in Cell Press, in the study “Multiple sclerosis risk gene Mertk is required for…

The European Commission (EC) has approved a new method to administer Tysabri (natalizumab) as a treatment for people with relapsing-remitting multiple sclerosis (RRMS). This new delivery route involves a subcutaneous injection in which Tysabri is injected under the skin. Compared with the previously approved intravenous (into the bloodstream) formulation,…

People who develop multiple sclerosis (MS) as children are more likely to attain lower education levels, earn less in the workplace, and be more reliant on disability benefits later in life, new research shows. These findings were published in JAMA Neurology, in the study, “Long-term Socioeconomic…

Treatment with the antioxidant N‐acetyl cysteine is well-tolerated, but failed to outperform a placebo at easing fatigue in people with progressive multiple sclerosis (MS), a small clinical trial found. More studies now are needed to determine if oxidative stress contributes to fatigue or clinical progression in MS patients, and…

A machine learning-based method that examines walking abnormalities in people with multiple sclerosis (MS) could help identify patients who are at high risk of worsening symptoms, a study suggests. The study, “Predicting Multiple Sclerosis from Gait Dynamics Using an Instrumented Treadmill – A Machine Learning Approach,”…

The U.S. Food and Drug Administration (FDA) has authorized the use of a medical device called Portable Neuromodulation Stimulator or PoNS as a short-term treatment for walking difficulties in people with multiple sclerosis (MS). PoNS, developed by Helius Medical Technologies, is a non-invasive medical device…

Injecting rituximab — a cancer therapy sometimes used in multiple sclerosis — into the spinal canal of people with progressive forms of MS did not demonstrably lower inflammation or improve clinical conditions, according to the results of a small trial. “Contrary to the initial high expectations, no clear-cut effect on…

People with multiple sclerosis (MS) who have more extensive mobility issues are more likely to have worse outcomes from COVID-19, a new study indicates. The study findings also indicate that COVID-19-associated outcomes are worse among MS patients who are Black, older, have heart-related diseases, and who were treated with…

The U.S. Food and Drug Administration (FDA) has approved Ponvory (ponesimod) as an oral treatment for adults with relapsing forms of multiple sclerosis (MS). The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). The treatment is taken as a…

In recognition of National Multiple Sclerosis (MS) Awareness Month — celebrated throughout March — Novartis and iHeartRadio are teaming up on a virtual event to celebrate the resilient spirit of people affected by MS. Called “A Night for MS Awareness,” the event will be streamed on…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Women with multiple sclerosis (MS) who continue taking disease-modifying therapies (DMTs) throughout pregnancy accrue lower non-maternity healthcare…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Reducing the essential amino acid methionine in the diet lessened multiple sclerosis (MS)-like symptoms in a mouse model of…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Dietary restriction can lessen the severity of multiple sclerosis (MS) by modulating levels of fat-related hormones, new research…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Clinical characteristics of multiple sclerosis (MS) patients, including their response to therapies, vary based on race and ethnicity,…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see all the latest stories from the conference. The fat-related hormone leptin has pro-inflammatory effects on immune cells, new data show, findings that help in better…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see all the latest stories from the conference. At the ACTRIMS Forum 2021, Rhonda Voskuhl, MD, a neurology professor at the University…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25-27. Go here to see all the latest stories from the conference. Factors in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord change with age and can affect…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25-27. Go here to see all the latest stories from the conference. People with multiple sclerosis (MS) who are less socioeconomically advantaged tend to have faster rates…

People with multiple sclerosis (MS) who smoke tobacco or are not physically active are more likely to experience fatigue that interferes with their daily life, a new study indicates. The findings suggest that physical exercise and quitting smoking could help ease fatigue in people with MS. The study, “…

Two global Phase 3 clinical trials testing the investigational oral medication evobrutinib are recruiting participants with relapsing forms of multiple sclerosis (MS). The two identically-designed trials — EVOLUTION RMS 1 (NCT04338022) and EVOLUTION RMS 2 (…

People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta (ofatumumab) over other methods for injecting treatments, according to a survey. The survey was conducted by Novartis, which markets Kesimpta. Full findings from the survey will be presented at…

The Scottish Medicines Consortium (SMC) has approved Zeposia (ozanimod) for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Zeposia is sold as a tablet, to be taken by mouth once daily. The SMC has recommended that Zeposia be prescribed for people with RRMS who experience relapses or have evidence of…

A novel medication targeting the protein folate receptor-beta (FR-beta) decreased inflammation and brain damage in a rat model of multiple sclerosis (MS). The findings were published in the Journal of Neuroinflammation, in the study “Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of…

The U.S. Food and Drug Administration (FDA) has approved an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into muscle, is what is typically used to deliver the flu shot. According to Biogen, Plegridy’s…

A branch of the European Medicines Agency (EMA) has recommended that Kesimpta (ofatumumab) be approved and made available to treat relapsing forms of multiple sclerosis (MS) in adults with active disease. A final decision from the European Commission (EC) is expected in about two months. Typically, the EC follows…